Overall venture investment in the sector remains steady, but the big strategics back off.
The group has finally revalued its troubled sleep franchise. So what now?
A clinical hit could allow the group’s liquid biopsy to expand from breast cancer to ovarian.
Paradise is now odds-on for US approval – but Medtronic’s rival device is not far behind.
The Pascal valve repair device boasts a pivotal hit and US approval, but can it compete?
Grail finds the path for its liquid biopsy less clear than it might have hoped.
Attempts to treat pain with non-opioid drugs have ended in repeated failures – but device makers have met with greater success.